Archive for the ‘Arena Pharmaceuticals Inc’ Category

Arena Pharmaceuticals

May 11th, 2015 | Posted in 2015, Arena Pharmaceuticals Inc

Arena Pharmaceuticals announced that, in conjunction with Eisai Inc, it has completed two randomized, crossover trials that demonstrate the efficacy of its extended release weight loss drug, lorcaserin.

Arena Pharmaceuticals

December 19th, 2014 | Posted in 2014, Arena Pharmaceuticals Inc

Arena Pharmaceuticals, San Diego, has been granted a new patent for its ralinepag drug for use in the treatment of pulmonary arterial hypertension.

Arena Pharmaceuticals

October 24th, 2013 | Posted in 2013, Arena Pharmaceuticals Inc

Arena Pharmaceuticals Inc., – Recently reported that Eisai Inc., (under an agreement with Arena to market and distribution Belviq in the USA),  will increase its Belviq Sales Force to about 400 representative by December 2013, doubling the size of the sales from force from when Belviq became available in June 2013. Belviq is approved by the […]

Arena Pharmaceuticals

June 12th, 2013 | Posted in 2013, Arena Pharmaceuticals Inc

Arena Pharmaceuticals – San Diego:  Has recently launched its new weight-loss drug, Belviq.

Arena Pharmaceuticals

April 8th, 2013 | Posted in 2013, Arena Pharmaceuticals Inc

Has started Phase I clinical testing of a potential treatment for diseases that affect the body’s immune systems.  In this preliminary test, Arena will evaluate the safety, tolerability and reaction to the drugs using up to 64 healthy adult volunteers.

Arena Pharmaceuticals Inc

May 21st, 2012 | Posted in 2012, Arena Pharmaceuticals Inc

Arena Pharmaceuticals Inc. – San Diego:  The company’s weight loss pill has gained the backing of an advisory panel, which puts the obesity drug in line for U.S. approval almost 2 year after regulators rejected it as too risky!! The FDA voted recently 18-4 that the benefits of the pill, known as Lorcaserin, outweigh the […]

Arena Pharmaceuticals Inc

March 25th, 2010 | Posted in Arena Pharmaceuticals Inc

Arena Pharmaceuticals Inc. is a biotechnology company in the development state.  The company announced that it has started early-stage studies of potential narcolepsy (a sleep disorder) and cataplexy (a sudden loss of muscle tone for people with Narcolepsy) treatment.